S. 4674Senate116th Congress (2019-2021)In Committee

Strengthening Medicaid Coverage of MAT Act

AI-Generated Summary

Updated April 14, 2026 at 3:05 PM UTC

The Strengthening Medicaid Coverage of MAT Act changes the Social Security Act so that any drug or biological product used for medication‑assisted treatment (MAT) and paid for through Medicaid must follow the Medicaid Drug Rebate Program rules. By treating MAT drugs as covered outpatient drugs, the bill ensures that manufacturers provide required rebates, which could lower costs for state Medicaid programs and improve access for patients receiving addiction treatment. The changes apply to Medicaid programs, patients using MAT, and drug manufacturers.

Key Provisions

Amends Section 1905 to add MAT drugs and biologics to the list of outpatient drugs that must meet Medicaid rebate requirements.
Specifies that these MAT drugs are considered “prescribed drugs” for rebate purposes, linking them to existing Medicaid coverage rules.
Updates Section 1927 to explicitly include MAT drugs and biologics in the rebate program’s definition.
Sets the effective date of the changes to be retroactive to the enactment of the SUPPORT for Patients and Communities Act.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

1 earlier action

SenateIntro Referral Latest Action

Read twice and referred to the Committee on Finance.

Finance Committee

September 23, 2020

View full timeline

SenateIntro Referral

Introduced in Senate

September 23, 2020

SenateIntro Referral

Read twice and referred to the Committee on Finance.

Finance Committee

September 23, 2020

Bill Text

Latest available legislative text

Reading Mode

Raw Text PDF XML

Introduced in SenateIssued September 23, 2020

116th CONGRESS

2d Session

S. 4674

IN THE SENATE OF THE UNITED STATES

September 23, 2020

Ms. Klobuchar (for herself and Ms. Smith) introduced the following bill; which was read twice and referred to the Committee on Finance

A BILL

To amend title XIX of the Social Security Act to clarify that drugs and biologicals used for medication-assisted treatment under Medicaid are subject to the requirements of the Medicaid Drug Rebate Program.

Short title

This Act may be cited as the Strengthening Medicaid Coverage of MAT Act.

Inclusion in the Medicaid drug rebate program of covered outpatient drugs used for medication-assisted treatment

(a)

In general

Section 1905 of the Social Security Act (42 U.S.C. 1396d) is amended—

(1)

in paragraph (29) of subsection (a)—

(A)

by moving the margin of such paragraph 2 ems to the right; and

(B)

by striking subject to paragraph (2) and inserting subject to paragraphs (2) and (3); and

(2)

in subsection (ee), by adding at the end the following:

(3)

Application of rebate requirements

The requirements of section 1927 shall apply to any drug or biological product described in paragraph (1)(A) that is—

(A)

furnished as medical assistance in accordance with subsection (a)(29) and section 1902(a)(10)(A); and

(B)

a covered outpatient drug (as defined in section 1927(k), except that, in applying paragraph (2)(A) of such section to a drug described in paragraph (1)(A), such drug shall be deemed a prescribed drug for purposes of subsection (a)(12)).

(b)

Conforming amendment

Section 1927(d)(7) of the Social Security Act (42 U.S.C. 1396r–8(d)(7)) is amended by adding at the end the following new subparagraph:

(D)

Drugs and biological products described in subsection (ee)(1)(A) of section 1905 that are furnished as medical assistance in accordance with subsection (a)(29) of such section and section 1902(a)(10)(A).

(c)

Retroactive effective date

The amendments made by this section shall take effect as if included in the enactment of section 1006(b) of the SUPPORT for Patients and Communities Act (Public Law 115–271; 132 Stat. 3914).